As Aier Eye Hospital Group (SZSE:300015) Ascends 4.0% This Past Week, Investors May Now Be Noticing the Company's Three-year Earnings Growth
If you love investing in stocks you're bound to buy some losers. But the long term shareholders of Aier Eye Hospital Group Co., Ltd. (SZSE:300015) have had an unfortunate run in the last three years.
Nomura Adjusts Aier Eye Hospital's Price Target to 15.35 Yuan From 22.14 Yuan, Keeps at Buy
04:55 AM EDT, 04/26/2024 (MT Newswires) -- Nomura Adjusts Aier Eye Hospital's Price Target to 15.35 Yuan From 22.14 Yuan, Keeps at Buy Price (RMB): ¥12.63, Change: ¥+0.39, Percent Change: +3.19%
Declining Stock and Solid Fundamentals: Is The Market Wrong About Aier Eye Hospital Group Co., Ltd. (SZSE:300015)?
With its stock down 13% over the past three months, it is easy to disregard Aier Eye Hospital Group (SZSE:300015). However, a closer look at its sound financials might cause you to think again. Give
Aier Eye Hospital Group Co., Ltd. (SZSE:300015) Investors Are Less Pessimistic Than Expected
When close to half the companies in China have price-to-earnings ratios (or "P/E's") below 32x, you may consider Aier Eye Hospital Group Co., Ltd. (SZSE:300015) as a stock to potentially avoid with it
Aier Ophthalmology (300015.SZ): Currently, it is the largest ophthalmology chain medical group in China. Many hospitals are gradually taking up the largest market share in the region in terms of outpatient visits, surgery volume, and revenue
Gelonghui, March 15 | Aier Ophthalmology (300015.SZ) said on the investor interactive platform that the company is currently the largest ophthalmology medical chain in China, and many hospitals are gradually occupying the largest market share in the region in terms of outpatient visits, surgery volume, and revenue. After years of development, the scale effect of the company is becoming more and more obvious, and its core competitiveness in terms of technology, brand, service, scale, talent, scientific research, and management has been further strengthened. China has a huge population base, and the penetration rate of ophthalmology specialists in all subdivisions is very low. As Chinese residents continue to increase their awareness of eye health and their income levels increase, the potential demand for ophthalmology care will continue
Aier Ophthalmology (300015.SZ): The optometry business is a complete system from prevention, control to treatment. In addition to low-concentration atropine, there are also various myopia prevention and control products such as OK lenses, defocused soft l
On March 14, Ge Longhui Ophthalmology (300015.SZ) said on the investor interactive platform that the company is closely following the progress and development of ophthalmology diagnosis and treatment technology at home and abroad. In terms of the prevention and control of myopia among young people, the company has obtained the “Medical Institution Formulation License”, its 0.05% atropine eye drops have obtained relevant approval, and the product has entered clinical practice. At this stage, the incidence of myopia is high, and there is a clear trend of getting younger and more advanced. The task of preventing and controlling myopia among young people is very heavy, and there is a growing demand for the use of prevention and control products. The company's optometry business is a complete system from prevention, control to treatment. In addition to low-concentration atropine, it also has OK lenses and defocus
Why You Should Care About Aier Eye Hospital Group's (SZSE:300015) Strong Returns On Capital
What are the early trends we should look for to identify a stock that could multiply in value over the long term? Typically, we'll want to notice a trend of growing return on capital employed (ROCE)
Nomura Adjusts Aier Eye Hospital Group's Price Target to 22.14 Yuan From 25.03 Yuan, Keeps at Buy.
04:16 AM EST, 02/29/2024 (MT Newswires) -- Nomura Adjusts Aier Eye Hospital Group's Price Target to 22.14 Yuan From 25.03 Yuan, Keeps at Buy. Price (RMB): ¥14.65, Change: ¥+0.27, Percent Change: +1.88
Aier Eye Hospital Group Co., Ltd.'s (SZSE:300015) Largest Shareholders Are Private Companies With 34% Ownership, Individual Investors Own 25%
Key Insights Significant control over Aier Eye Hospital Group by private companies implies that the general public has more power to influence management and governance-related decisions A total of
Estimating The Fair Value Of Aier Eye Hospital Group Co., Ltd. (SZSE:300015)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Aier Eye Hospital Group fair value estimate is CN¥14.24 Aier Eye Hospital Group's CN¥12.51 share price indicates it is trading at similar lev
Aier Ophthalmology (300015.SZ): A total cost of 204 million yuan to buy back 11.31 million shares
Gelonghui, Feb. 2 | Aier Ophthalmology (300015.SZ) announced that up to now, the company has repurchased 11,310,377 shares of the company through a special stock repurchase account, accounting for 0.12% of the company's total share capital. The highest transaction price is 18.56 yuan/share, the lowest transaction price is 16.92 yuan/share, and the total transaction amount is 203,616,286.52 yuan.
Aier Ophthalmology accelerates expansion and market attitudes are now divided under the merger and acquisition model with high goodwill
“Investor Network” Xie Yingjie At the beginning of the new year, Aier Eye Hospital Group Co., Ltd. (hereinafter referred to as “Aier Ophthalmology”, 300015.SZ) once again revealed that its hospitals were punished for reusing disposable medical devices. As a leading enterprise in the domestic ophthalmology chain, Aier Ophthalmology excels at its merger and acquisition fund model, supporting performance through continuous acquisition of hospitals. However, the increasing scale has also brought about internal control problems. Medical disputes have repeatedly caused public opinion crises, and the market's attitude towards Aier Ophthalmology is quite divided. Some institutions take into account the ever-increasing needs of ophthalmology for diagnosis and treatment, and the company is stable
Aier Eye Hospital Group's (SZSE:300015) Five-year Total Shareholder Returns Outpace the Underlying Earnings Growth
It hasn't been the best quarter for Aier Eye Hospital Group Co., Ltd. (SZSE:300015) shareholders, since the share price has fallen 14% in that time. Looking further back, the stock has generated go
Aier Ophthalmology (300015.SZ): The Aier brand is getting better and more resistant to risks
Gelonghui, January 18 | Aier Ophthalmology (300015.SZ) said on the investor interactive platform that the Aier brand is improving and has strong resilience to risks. Since its launch, it has achieved continuous healthy growth regardless of good or bad circumstances. Compared with 2019, the company's operating income increased by 61.26% and attributed net profit increased by 83.06%.
Aier Ophthalmology was fined for reusing disposable medical equipment, and Xiangyang Aier Ophthalmology was fined 5,000 for violating disinfection regulations
According to the Tianyancha App, recently, Xiangyang Aier Eye Hospital Co., Ltd. was fined 5,000 yuan by the Xiangyang Municipal Health Commission for reusing disposable medical devices due to failure to implement relevant national regulations, standards and regulations in disinfection management. Xiangyang Aier Eye Hospital Co., Ltd. was established in August 2008. The legal representative is Wei Liang, with a registered capital of 18 million yuan, wholly-owned by Aier Ophthalmology (300015).
Aier Eye Hospital Group Co., Ltd.'s (SZSE:300015) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
With its stock down 20% over the past three months, it is easy to disregard Aier Eye Hospital Group (SZSE:300015). However, a closer look at its sound financials might cause you to think again. Give
Aier Ophthalmology (300015.SZ): A total cost of about 204 million yuan to buy back 113.104 million shares
Gelonghui, January 2 | Aier Ophthalmology (300015.SZ) announced that up to now, the company has repurchased 113.103.77 million shares of the company's shares through a special stock repurchase account, accounting for 0.12% of the company's total share capital. The highest transaction price is 18.56 yuan/share, the minimum transaction price is 16.92 yuan/share, and the total transaction amount is 204 million yuan (excluding transaction fees).
Aier Eye Hospital Group Co., Ltd.'s (SZSE:300015) Share Price Could Signal Some Risk
Aier Eye Hospital Group Co., Ltd.'s (SZSE:300015) price-to-earnings (or "P/E") ratio of 43.9x might make it look like a sell right now compared to the market in China, where around half of the compan
Aier Eye Hospital Group (SZSE:300015) Is Aiming To Keep Up Its Impressive Returns
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. One common approach is to try and find a company with returns on capital employed (ROCE) that ar
Aier Ophthalmology (300015.SZ) has repurchased a total of 113.104 million shares at a cost of 204 million yuan
Aier Ophthalmology (300015.SZ) issued an announcement. Up to now, the company has used a special stock repurchase account to collect...
No Data